|
1
|
Capitanio U and Montorsi F: Renal cancer.
Lancet. 387:894–906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eggener SE, Yossepowitch O, Pettus JA,
Snyder ME, Motzer RJ and Russo P: Renal cell carcinoma recurrence
after nephrectomy for localized disease: Predicting survival from
time of recurrence. J Clin Oncol. 24:3101–3106. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
National Comprehensive Cancer Network, .
Guidelines are available at. https://www.nccn.org/professionals/physician_gls/default.aspx
|
|
4
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili
R, Bjarnason GA, et al: Overall survival and updated results for
sunitinib compared with interferon alfa in patients with metastatic
renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Motzer RJ, Michaelson MD, Redman BG, Hudes
GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE,
et al: Activity of SU11248, a multitargeted inhibitor of vascular
endothelial growth factor receptor and platelet-derived growth
factor receptor, in patients with metastatic renal cell carcinoma.
J Clin Oncol. 24:16–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motzer RJ, Rini BI, Bukowski RM, Curti BD,
George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G,
et al: Sunitinib in patients with metastatic renal cell carcinoma.
JAMA. 295:2516–2524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barrios CH, Hernandez-Barajas D, Brown MP,
Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A,
et al: Phase II trial of continuous once-daily dosing of sunitinib
as first-line treatment in patients with metastatic renal cell
carcinoma. Cancer. 118:1252–1259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Motzer RJ, Hutson TE, Olsen MR, Hudes GR,
Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D,
et al: Randomized phase II trial of sunitinib on an intermittent
versus continuous dosing schedule as first-line therapy for
advanced renal cell carcinoma. J Clin Oncol. 30:1371–1377. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gore ME, Szczylik C, Porta C, Bracarda S,
Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano
D, et al: Safety and efficacy of sunitinib for metastatic
renal-cell carcinoma: An expanded-access trial. Lancet Oncol.
10:757–763. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gore ME, Szczylik C, Porta C, Bracarda S,
Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E,
et al: Final results from the large sunitinib global
expanded-access trial in metastatic renal cell carcinoma. Br J
Cancer. 113:12–19. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Motzer RJ, Hutson TE, Cella D, Reeves J,
Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et
al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morais C: Sunitinib resistance in renal
cell carcinoma. J Kidney Cancer VHL. 1:1–11. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamaguchi N, Osaki M, Onuma K, Yumioka T,
Iwamoto H, Sejima T, Kugoh H, Takenaka A and Okada F:
Identification of MicroRNAs involved in resistance to sunitinib in
renal cell carcinoma cells. Anticancer Res. 37:2985–2992.
2017.PubMed/NCBI
|
|
14
|
Yumioka T, Osaki M, Sasaki R, Yamaguchi N,
Onuma K, Iwamoto H, Morizane S, Honda M, Takenaka A and Okada F:
Lysosome-associated membrane protein 2 (LAMP-2) expression induced
by miR-194-5p downregulation contributes to sunitinib resistance in
human renal cell carcinoma cells. Oncol Lett. 15:893–900.
2018.PubMed/NCBI
|
|
15
|
Eskelinen EL, Cuervo AM, Taylor MR,
Nishino I, Blum JS, Dice JF, Sandoval IV, Lippincott-Schwartz J,
August JT and Saftig P: Unifying nomenclature for the isoforms of
the lysosomal membrane protein LAMP-2. Traffic. 6:1058–1061. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Punt S, Houwing-Duistermaat JJ, Schulkens
IA, Thijssen VL, Osse EM, de Kroon CD, Griffioen AW, Fleuren GJ,
Gorter A and Jordanova ES: Correlations between immune response and
vascularization qRT-PCR gene expression clusters in squamous
cervical cancer. Mol Cancer. 14:712015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gotink KJ, Broxterman HJ, Labots M, de
Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters
RJ, Jansen G, et al: Lysosomal sequestration of sunitinib: A novel
mechanism of drug resistance. Clin Cancer Res. 17:7337–7346. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pérez L, McLetchie S, Gardiner GJ, Deffit
SN, Zhou D and Blum JS: LAMP-2C Inhibits MHC Class II presentation
of cytoplasmic antigens by disrupting chaperone-mediated autophagy.
J Immunol. 196:2457–2465. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dice JF: Chaperone-mediated autophagy.
Autophagy. 3:295–299. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Endo Y, Furuta A and Nishino I: Danon
disease: A phenotypic expression of LAMP-2 deficiency. Acta
Neuropathol. 129:391–398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Goldsmith J, Levine B and Debnath J:
Autophagy and cancer metabolism. Methods Enzymol. 542:25–57. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ng G and Huang J: The significance of
autophagy in cancer. Mol Carcinog. 43:183–187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Notte A, Leclere L and Michiels C:
Autophagy as a mediator of chemotherapy-induced cell death in
cancer. Biochem Pharmacol. 82:427–434. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu J, Fan L, Wang H and Sun G: Autophagy,
a double-edged sword in anti-angiogenesis therapy. Med Oncol.
33:102016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Giuliano S, Cormerais Y, Dufies M, Grépin
R, Colosetti P, Belaid A, Parola J, Martin A, Lacas-Gervais S,
Mazure NM, et al: Resistance to sunitinib in renal clear cell
carcinoma results from sequestration in lysosomes and inhibition of
the autophagic flux. Autophagy. 11:1891–1904. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Adelaiyr R, Ciamporcero E, Miles KM,
Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S,
Ku SY, et al: Sunitinib dose escalation overcomes transient
resistance in clear cell renal cell carcinoma and is associated
with epigenetic modifications. Mol Cancer Ther. 14:513–522. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sasaki K, Tsuno NH, Sunami E, Tsurita G,
Kawai K, Okaji Y, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M, et al:
Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on
colon cancer cells. BMC Cancer. 10:3702010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li ML, Xu YZ, Lu WJ, Li YH, Tan SS, Lin
HJ, Wu TM, Li Y, Wang SY and Zhao YL: Chloroquine potentiates the
anticancer effect of sunitinib on renal cell carcinoma by
inhibiting autophagy and inducing apoptosis. Oncol Lett.
15:2839–2846. 2018.PubMed/NCBI
|
|
31
|
Wiedmer T, Blank A, Pantasis S, Normand L,
Bill R, Krebs P, Tschan MP, Marinoni I and Perren A: Autophagy
inhibition improves sunitinib efficacy in pancreatic neuroendocrine
tumors via a lysosome-dependent mechanism. Mol Cancer Ther.
16:2502–2515. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fujiwara Y, Furuta A, Kikuchi H, Aizawa S,
Hatanaka Y, Konya C, Uchida K, Yosihmura A, Tamai Y, Wada K and
Kabuta T: Discovery of a novel type of autophagy targeting RNA.
Autophagy. 9:403–409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fujiwara Y, Kikuchi H, Aizawa S, Furuta A,
Hatanaka Y, Konya C, Uchida K, Wada K and Kabuta T: Direct uptake
and degradation of DNA by lysosomes. Autophagy. 9:1167–1171. 2013.
View Article : Google Scholar : PubMed/NCBI
|
